Chimerix Sees Options For Brincidofovir Despite Disappointing CMV Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is analyzing data from subsets of patients in the Phase III SUPPRESS trial evaluating brincidofovir for the prevention of cytomegalovirus in patients undergoing hematopoietic cell transplantation.